CASI Pharmeceuticals

Clinical

Clinical Trials

Clinical Trials Currently Enrolling

Please contact the individual trial centers listed below for enrollment information. You may also click on the clinicaltrials.gov link for specific trial information.

Product Candidate Location Principal Investigator Indication Phase Contact
ENMD-2076 MSKCC Ghassan Abou-Alfa, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 University of CO, Denver Stephen Leong, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 Dana-Farber Cancer Inst. Rober Mayer, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 University of CA, San Francisco John Gordan, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 UT, Southwestern Muhmmad Beg, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China XU, Binghe, MD TNBC II Ken Ren, MD. kenr@casipharmaceuticals.com

Ongoing Trials, Enrollment Closed

Product Candidate Location Principal Investigator Indication Phase
ENMD-2076 Princess Margaret Hospital Malcolm Moore, MD Albiruni R.A. Razak, MD Advanced/Metastatic Soft Tissue Sarcoma II
ENMD-2076 Multi-center Amit M. Oza, MD Ovarian Clear Cell Carcinoma II
ENMD-2076 University of Colorado Cancer Center Jennifer Diamond, MD Triple-Negative Breast Cancer II
ENMD-2076 Indiana University Melvin and Bren Simon Cancer Center Kathy Miller, MD Triple-Negative Breast Cancer II
ENMD-2076 University of Colorado and Dana-Farber Cancer Institute Dr. Wells Messersmith & Dr. Geoffrey Shaprio Advanced Cancers I

* NCI-sponsored trial. CASI Pharmaceuticals provided only the study drug for this trial.
** NCI-sponsored trial. CASI Pharmaceuticals provided only the study drug for this trial.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Rodman & Renshaw 19th Annual Global Investment Conference

Download →

Poster

Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret Phase 2 consortium

Download →